Analysis updated on Oct. 13, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
On Oct. 13, 2026, VNRX is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5379 stocks scored that day.
Volitionrx Ltd is a small-cap company with a market capitalization of $3M. It ranks number 15 by market capitalization among the 15 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast. Its Current Ratio of 0.30x is the lowest of the 15 peers that report one.
A per-ticker accuracy statistic for VNRX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.9% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, VNRX included.
Follow VNRX free90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.
| Metric | VNRX | Rank |
|---|---|---|
| Market Cap | $3M | 15/15 |
| EPS | $-1.01 | – |
| Revenue/Share | $0.18 | – |
| FCF/Share | $-1.43 | – |
| Metric | VNRX | Rank |
|---|---|---|
| Operating Margin | -790.2% | 10/14 |
| EBT Margin | -790.2% | 10/14 |
| Metric | VNRX | Rank |
|---|---|---|
| Current Ratio | 0.30x | 15/15 |
| Interest Coverage | -35.5x | 10/14 |
| Working Capital | -$9M | 15/15 |
| Metric | VNRX | Rank |
|---|---|---|
| Operating Cash Flow | -$20M | 11/16 |
| Free Cash Flow | -$20M | 6/10 |
| Capital Spending | -$20K | 1/10 |
| FCF/Sales | -796.8% | 7/10 |
| CapEx/Sales | 0.9% | 10/10 |
| Metric | VNRX | Rank |
|---|---|---|
| Asset Turnover | 0.30x | 7/12 |
| Receivables Turnover | 8.9x | 2/11 |
| Fixed Assets Turnover | 0.7x | 9/12 |
| Days Sales Outstanding | 41 days | 10/11 |
| Metric | VNRX | Rank |
|---|---|---|
| Total Revenue | $2M | 9/12 |
| Operating Income | -$19M | 10/15 |
| R&D Expense | $9M | 10/16 |
| SG&A Expense | $18M | 8/12 |
| Metric | VNRX | Rank |
|---|---|---|
| Shares Outstanding | 14M | – |
| EPS Growth | -496.6% | – |
| Total Current Assets | $4M | |
| Cash & Short-term Investments | $3M | |
| Accounts Receivable | $280K | |
| Total Liabilities | $42M | |
| Short-term Debt | $10M |
Companies classified under the same SEC industry code as Volitionrx Ltd (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| VNRX Volitionrx Ltd | ▶ | $3M |
| IDXX Idexx Laboratories Inc /De | ▼ | $40.99B |
| LNTH Lantheus Holdings, Inc. | ▼ | $6.53B |
| NEOG Neogen Corp | ▲ | $2.56B |
| CLDX Celldex Therapeutics, Inc. | ▲ | $2.22B |
| NTLA Intellia Therapeutics, Inc. | ▲ | $1.67B |
| QDEL Quidelortho Corp | ▲ | $967M |
| ACHV Achieve Life Sciences, Inc. | ▲ | $720M |
| TKNO Alpha Teknova, Inc. | ▲ | $441M |
| MYGN Myriad Genetics Inc | ▲ | $390M |
| IMDX Insight Molecular Diagnostics Inc. | ▲ | $98M |
| ICCC Immucell Corp /De/ | ▲ | $87M |
| AWHL Aspira Women's Health Inc. | ▲ | $12M |
| BMRA Biomerica Inc | ▲ | $8M |
| CDIO Cardio Diagnostics Holdings, Inc. | ▲ | $5M |
| QCLS Q/C Technologies, Inc. | ▼ | N/A |
| TRIB Trinity Biotech Plc | ▶ | N/A |
Based on the one-year price targets offered by 5 analysts, the average target price for VolitionRX Ltd (VNRX) is $3.13, with a high estimate of $5.00 and a low estimate of $2.00. The average target ...
Based on the one-year price targets offered by 4 analysts, the average target price for VolitionRX Ltd (VNRX) is $3.16 with a high estimate of $5.00 and a low estimate of $2.00. The average target ...
VolitionRx Ltd focuses on pioneering blood-based tests for cancer and other diseases, targeting a diagnostics market ripe for disruption. For you as an investor in the United States and ...
On Oct. 13, 2026, VNRX is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5379 stocks scored that day.
A per-ticker accuracy statistic for VNRX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Volitionrx Ltd forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
17 issuers in our coverage, VNRX included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.